Caribou Biosciences (CRBU) Revenue (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Revenue data on file, last reported at $2.4 million in Q1 2026.

• On a quarterly basis, Revenue rose 1.87% year-over-year to $2.4 million in Q1 2026; TTM through Mar 2026 was $11.2 million, a 12.96% increase from a year earlier, with the FY2025 full-year figure at $11.2 million, up 11.66% from the prior year.
• Revenue for Q1 2026 stood at $2.4 million, down from $3.9 million in the prior quarter.
• Over the last five years, Revenue for CRBU reached as high as $23.7 million in Q3 2023 and fell as low as $2.0 million in Q3 2024.
• Historically, Revenue has averaged $4.2 million across 5 years, with a median of $3.3 million in 2022.
• Across the five-year window, Revenue surged 616.38% in 2023 and sank 91.45% in 2024, its largest moves.
• Year by year, Revenue stood at $3.7 million in 2022, then dropped by 3.63% to $3.6 million in 2023, then plunged by 41.62% to $2.1 million in 2024, then jumped by 89.74% to $3.9 million in 2025, then slumped by 39.18% to $2.4 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $2.4 million in Q1 2026, $3.9 million in Q4 2025, and $2.2 million in Q3 2025.